Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

TheFly reported on May 28 that Morgan Stanley upgraded HCM to Equal Weight from Underweight and set a new price target of $13.60, slightly below the prior $13.7...